Randomized phase III trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.

Trial Profile

Randomized phase III trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-Hodgkin's lymphoma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Rituximab (Primary)
  • Indications B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms RESORT
  • Most Recent Events

    • 10 Dec 2013 Pharmacogenomic analysis of follicular lymphoma patients presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
    • 10 Dec 2012 Patient-reported outcomes and QOL data (n=253) presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Mar 2012 Planned end date changed from 1 Apr 2010 to 1 Apr 2012 as reportd by ClinicalTrials.gov record (Parent trial; NCT00075946).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top